Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Eur Ann Allergy Clin Immunol ; 52(2): 51-61, 2020 03.
Article in English | MEDLINE | ID: mdl-31994369

ABSTRACT

Summary: Tryptase is a serin-protease produced and released by mast cells after IgE-mediated or non-IgE mediated stimuli. We here review the various aspects related to the molecular characteristics of the enzyme and its biological effects, the genetic basis of its production and the release kinetics. Recommendations for the clinical use of tryptase measurement developed by a task force of Società Italiana di Patologia Clinica e Medicina di Laboratorio and Associazione Allergologi Immunologi Italiani Territoriali e Ospedalieri are given on the best procedure for a correct definition of the reference values in relation to the inter-individual variability and to the correct determination of tryptase in blood and other biological liquids, in the diagnosis of anaphylaxis (from drugs, food, insect sting, or idiophatic), death from anaphylaxis (post mortem assessment) and cutaneous or clonal mastcell disorders.


Subject(s)
Allergy and Immunology , Anaphylaxis/diagnosis , Biomarkers/blood , Leukemia, Biphenotypic, Acute/diagnosis , Mastocytoma/diagnosis , Mastocytosis/diagnosis , Tryptases/blood , Advisory Committees , Animals , Autopsy , Humans , Immunoglobulin E/metabolism , Italy , Practice Guidelines as Topic , Reproducibility of Results
2.
J Eur Acad Dermatol Venereol ; 34(6): 1286-1292, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31953891

ABSTRACT

BACKGROUND: Most birch pollen-allergic patients develop allergic cross-reactions to the major allergen found in apples Mal d1, known as pollen-related food allergy (prFA). This is due to a strong clinically relevant homology between the major allergen in birch Bet v 1 and Mal d 1. Daily apple consumption induces oral tolerance in prFA, but its effect on the inhalational allergy has not been investigated. OBJECTIVES: As continuous apple consumption might also mitigate the inhalational allergy, this study aimed to uncover apple cultivars suitable for treatment of birch pollen rhinoconjunctivitis and apple allergy in a controlled and established dosage. METHODS: Patients (n = 52) with birch pollen allergy and prFA to apples were subjected to a prick-to-prick test (SPT) with 23 cultivars (red-fleshed, old traditional and new commercial). By SPT, the apple parts flesh, peel equatorial and peel apical near the stalk were compared for their reactivity. One apple cultivar of each allergenicity class (low, middle and high) was subsequently tested in an oral provocation test (OPT). RESULTS: According to the SPTs, we provide a ranking of all 23 cultivars. Red-fleshed apples displayed the lowest reactivity, followed by old and new cultivars. Four cultivars showed disagreement from their allergenicity class: Santana and Pink Lady®, new cultivars that provoked only low to moderate. In contrast, White Rosemary and Goldparmäne, two old cultivars, induced strong reactions. Skin reactivity increased from flesh to peel to stalk, and SPT results could predict the severity of prFA of each allergenicity class. CONCLUSIONS: Herein, we propose a treatment protocol for allergen immunotherapy to birch pollen and prFA with daily apple consumption. Red-fleshed, old and the new cultivars Santana and Pink Lady® provoke less allergic reactions and are suitable for initial induction. After a controlled and well-tolerated increase of intake, also moderate and finally high allergenic apple cultivars should be integrated into treatment of birch pollen allergenic patients.


Subject(s)
Food Hypersensitivity , Malus , Rhinitis, Allergic, Seasonal , Allergens , Betula , Desensitization, Immunologic , Food Hypersensitivity/therapy , Humans , Immunoglobulin E , Rhinitis, Allergic, Seasonal/therapy , Skin Tests
3.
Immunol Res ; 65(1): 370-374, 2017 02.
Article in English | MEDLINE | ID: mdl-27743128

ABSTRACT

The IIF using the HEp-2 cell substrate should be still considered the "gold standard" techniques for determination of antinuclear antibody (ANA). Standardization and automation can be considered to be still in progress. Aim of this study was to evaluate the performance of the commercially automated indirect immunofluorescent antinuclear HEp-2 antibody assay. The study was designed to compare two commercially available HEp-2 ANA by indirect immunofluorescent antibody assays using a sensitivity panel (120 clinically determined patients) and a specificity panel consisting of 78 clinically confirmed negative patients. We compared the NOVA View® system [INOVA Diagnostics San Diego, USA] with the new HELIOS Processor from AESKU Systems/AESKU.Diagnostics (Wendelsheim, Germany) to assess their capability for screening, pattern recognition and titration of the samples. These automated methods were directly compared to manual reading of the same processed slides on respective microscopes and also compared with the known clinical information. The results of the two automated methods were in very good agreement with recognizing negative and positive samples. The HELIOS system detected 188 samples correctly as negative or positive versus 187 detected by the NOVA View® system. The diagnostic sensitivity of the systems was 95.8 versus 96.7 % for HELIOS and NOVA View®, respectively. The systems exhibited a diagnostic specificity of 93.5 % for the HELIOS system and 91.0 % for the NOVA View®. Both systems are suitable for fast and reliable detection of positivity/negativity due to their high sensitivity and will lead to a further increase of standardization in autoimmunity.


Subject(s)
Antibodies, Antinuclear/blood , Autoimmune Diseases/blood , Autoimmune Diseases/immunology , Automation, Laboratory , Cell Line, Tumor , Fluorescent Antibody Technique, Indirect/methods , Humans , Sensitivity and Specificity
4.
Eur Arch Otorhinolaryngol ; 270(2): 565-70, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22588193

ABSTRACT

The upper airway respiratory diseases (i.e. common cold, allergic rhinitis, nonallergic/vasomotor rhinitis, acute and chronic rhinosinusitis and nasal polyposis) in which nasal congestion is a common symptom are often undertreated due to the frequent inadequate efficacy and safety concern with current therapies. In scientific literature, few studies seem to support the hypothesis that nasal inhalatory treatment with thermal water promotes the improvement of nasal symptoms, even if the mechanisms by which the improvement from SPA therapy can be expected remain debated. A prospective comparative study with a pre-post design has been performed consecutively enrolling 33 (males 70 %) patients of both genders older than 12 years of age, affected by chronic sinonasal inflammation. All patients underwent a 14-days course of radioactive water warm vapour inhalations followed by nasal aerosol of the same thermal water 10 min each once/day at Merano Therme. At the beginning and end of the study, in all the subjects, nasal function evaluation by active anterior rhinomanometry, mucociliary transport time (MCTt) determination and nasal cytology were performed. After the inhalatory treatment, the mucociliary function was improved and the pathologic mucociliary transport times recorded at the beginning of the study being significantly reduced to physiologic ones. Besides, before treatment, the cytologic picture showed an inflammatory cell infiltration (eosinophils, neutrophils with/without bacteria, mast cells) in 37 % of patients; after therapy in 66 % of these patients, the rhinocytogram was normal. Our results suggest, according to the literature data, that SPA therapy with radioactive water could represent an alternative choice in chronic inflammatory diseases of the upper airways, nonresponsive to pharmacological therapy.


Subject(s)
Balneology , Rhinitis/therapy , Sinusitis/therapy , Chronic Disease , Female , Humans , Male , Mucociliary Clearance , Nasal Mucosa/pathology , Nasal Obstruction/etiology , Rhinitis/complications , Rhinitis/physiopathology , Sinusitis/complications , Sinusitis/physiopathology
5.
Immunol Invest ; 39(2): 186-95, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20136624

ABSTRACT

The aim of this work was to evaluate the diagnostic accuracy of three different analytical methods for the detection of antineuronal antibodies and outline how they might be used to diagnose Paraneoplastic Neurological Syndromes (PNS) in a more effectively and rationally way. One hundred and four patients with neurological diseases were studied: 38 with paraneoplastic neurological disorder, 44 with other neurological diseases, and 22 with systemic autoimmune diseases and neurological disorders. 20 healthy subjects and 18 subjects with tumour without neurological disorders were also studied. Antineuronal antibodies were tested using three methods: Western blot (WB); Line-blot (LB); and indirect immunofluorescence (IIF) on primate cerebellum. The diagnostic sensitivity of the IIF, WB and LB methods was 28.9%, 26.3% and 36.8%, respectively, and their specificity was 95.2%, 97.1% and 98.1% respectively. The combined use of the three methods brought the sensitivity to 39.4%. The results of this study show that the methods used in clinical laboratories for the detection of antineuronal antibodies have good specificity. Among the three methods assessed, LB showed the highest diagnostic accuracy and also allowed for recognition of fine antibody specificities. According to these results we can suggest that LB should be used as the method of choice to search for paraneoplastic antibodies.


Subject(s)
Diagnostic Techniques, Neurological , Nerve Tissue Proteins/immunology , Paraneoplastic Syndromes, Nervous System/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Antibodies, Neoplasm/immunology , Autoantibodies/blood , Autoantibodies/immunology , Autoimmune Diseases of the Nervous System/diagnosis , Autoimmune Diseases of the Nervous System/immunology , Blotting, Western , Cerebellum/immunology , Cerebellum/metabolism , Female , Fluorescent Antibody Technique , Humans , Immunoblotting , Male , Middle Aged , Paraneoplastic Syndromes, Nervous System/blood , Paraneoplastic Syndromes, Nervous System/immunology , Sensitivity and Specificity , Young Adult
6.
Lupus ; 19(8): 906-12, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20179169

ABSTRACT

The aim of this study was to evaluate the diagnostic performance of four new enzyme immunoassays (EIAs) for anti-double-stranded-DNA (anti-dsDNA) antibodies, in comparison with the Farr assay and the Crithidia luciliae immunofluorescence test (CLIFT). To this purpose, sera from four patient groups were collected: 52 sera from patients with systemic lupus erythematosus (SLE); 28 from patients with other connective tissue diseases (CTD); 36 from patients with hepatitis C virus (HCV) infection; and 24 from those with acute viral infection. All sera were tested for anti-dsDNA antibodies by four EIA methods using a different antigenic DNA source [synthetic oligonucleotide (Method A), circular plasmid (Method B), recombinant (Method C), and purified extracted (Method D)], and by CLIFT and Farr assays. The diagnostic sensitivity of the assays was as follows: 84.6% (Method A), 73% (B), 82.7% (C), 84.6% (D), 55.8% (CLIFT), and 78.8% (Farr). Specificity was 82.9% (A), 97.7% (B), 96.5% (C), 94.3% (D), 96.5% (CLIFT), and 90.9% (Farr). From these data, we can conclude that the new-generation EIA methods evaluated in this study have higher sensitivity than the CLIFT and Farr assays and, with the exception of Method A, have specificity similar to the CLIFT and slightly higher than the Farr assay. These findings suggest that EIA tests may replace CLIFT as a screening test and the Farr assay as a specific test, for anti-dsDNA antibody detection.


Subject(s)
Antibodies, Antinuclear , Crithidia/immunology , Enzyme-Linked Immunosorbent Assay/methods , Fluorescent Antibody Technique/methods , Lupus Erythematosus, Systemic , Radioimmunoprecipitation Assay/methods , Adult , Antibodies, Antinuclear/blood , Antibodies, Antinuclear/immunology , DNA/immunology , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity
7.
J Clin Lab Anal ; 20(5): 184-9, 2006.
Article in English | MEDLINE | ID: mdl-16960894

ABSTRACT

The association between celiac disease (CD) and primary biliary cirrhosis (PBC) is well documented in medical literature; however, a high frequency of false positive results of the anti-transglutaminase (anti-tTG) test has been reported in patients with PBC. To verify if the positive results for anti-tTG autoantibody are false positives due to cross reactivity with mitochondrial antigens, we studied 105 adult patients affected with PBC, positive for anti-mitochondrial M2 antibodies. Anti-tTG IgA antibodies were studied by using six different immunoenzymatic assays that employ the tTG antigen obtained from different sources (human recombinant, placenta, red blood cells, and guinea pig liver). On the whole, 28 out of 105 PBC subjects tested positive for anti-tTG IgA antibodies, but only two were eventually found to be affected by CD; the other 26 were shown to be false positive. The specificity of the various antigenic substrates ranged from 88.5% of the human erythrocytes tTG to 97.1% of the human recombinant tTG. The results of this study showed that a true association between PBC and CD was present in only 2% of the patients and that, in most cases, the false positive results were attributable to the type of substrate utilized in the assay.


Subject(s)
Antibody Specificity/immunology , GTP-Binding Proteins/immunology , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Liver Cirrhosis, Biliary/immunology , Transglutaminases/immunology , Adult , Aged , Animals , Enzyme-Linked Immunosorbent Assay , Female , Guinea Pigs , Humans , Liver Cirrhosis, Biliary/diagnosis , Male , Middle Aged , Protein Glutamine gamma Glutamyltransferase 2
8.
Clin Rheumatol ; 24(5): 453-9, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16328603

ABSTRACT

Reports of a possible correlation between anti-Scl-70 antibody concentration and clinical manifestations in systemic sclerosis patients have recently appeared in the scientific literature. The goal of our study was to evaluate, by means of a multicenter study, the analytical reliability of immunoassay systems in the quantitative measurement of Scl-70 antibodies. Three blind samples (H, M, L) at different anti-Scl-70 antibody concentrations, and a low concentration antibody serum (LPC) used as a common calibrator, were sent three times in a 6-month time span to 39 Italian clinical laboratories. Each laboratory was asked to calculate dosages following the enzyme-linked immunosorbent assay (ELISA) method they used and report the optical density values of each sample (ODs), of the cutoff serum provided by the manufacturer of the kit used (ODco) and of LPC (ODLPC). The overall analytical imprecision (between methods and between laboratories) of the three different determinations of the values respectively expressed in ODs, ODs/ODco and ODs/ODLPCratio was 47.1, 52.8 and 34.0% for sample H, 56.2, 47.4% and 34% for sample M and 84.6, 86.0 and 86.6% for sample L. The average intra-method analytical imprecision was, respectively, 20.7, 29.8 and 18.6% for sample H, 24.6, 26.5 and 19.3% for sample M, and 30.6, 28.1 and 20.2% for sample L. The commercial ELISA methods currently used to determine the presence of anti-Scl-70 autoantibodies show considerable differences in the quantitative determination. The best results for reproducibility analyses have been obtained when the values were expressed as a ratio between the ODs of the sample and of the common calibrator (ODs/ODLPC). Forward-looking clinical studies that can clarify the usefulness of quantitative determination of anti-Scl-70 antibodies in the monitoring of diffuse scleroderma patients can be performed only when standard serum with a known antibody concentration and calibration curves for quantitative ELISA measurements are made available.


Subject(s)
Autoantibodies/analysis , Enzyme-Linked Immunosorbent Assay/methods , Nuclear Proteins/analysis , Autoimmune Diseases/diagnosis , Autoimmune Diseases/immunology , Biomarkers/analysis , DNA Topoisomerases, Type I , Humans , Italy , Predictive Value of Tests , Reagent Kits, Diagnostic , Reproducibility of Results , Statistics as Topic
9.
Ann N Y Acad Sci ; 1050: 348-56, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16014551

ABSTRACT

Retrospective studies have demonstrated that anti-annexin V (anti-AnxV) antibodies are linked to miscarriage. Their predictive value is, however, unknown. We have carried out a prospective study to evaluate the relationship between anti-AnxV antibodies and the pregnancy outcome. A serum sample was taken from 1038 consecutive healthy women at the beginning of pregnancy. IgG and IgM anti-AnxV antibodies were measured by an ELISA method. The cutoff value was set at 5 units for both IgG and IgM. Out of 1038 women, 116 (11.4%) had a miscarriage by the 22nd week; 10 were lost to follow-up, 10 had an induced abortion, 6 had a preterm delivery, and 896 carried their pregnancy through to term. An adverse outcome of the pregnancy proved to be directly related to the number of previous miscarriages (P = .008) and the age of the woman (P = .002). IgG and IgM anti-AnxV were present in 25% and 27% of the women who miscarried, and in 23% and 28% of those who gave birth (mean antibody concentration IgG, 4.2 vs. 4.4 U/mL; IgM, 3.7 vs. 3.5 U/mL). IgG and IgM anticardiolipin and anti-beta(2)GPI, together with antinuclear, antithyroperoxidase, and antithyroglobulin antibodies, were also measured in the 116 sera of the women with miscarriage and in an equal number of women who gave birth. Their positivity or level proved not to be useful in discriminating between the risk of miscarriage and term delivery. This large-scale prospective study demonstrates that the presence of IgG and IgM anti-AnxV antibodies, when measured in healthy women, does not give a positive predictive lead towards the possibility of a miscarriage, and it is not useful in evaluating the risk of miscarriage at the beginning of pregnancy.


Subject(s)
Abortion, Spontaneous/immunology , Annexin A5/immunology , Antibodies, Anti-Idiotypic/immunology , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Adolescent , Adult , Antibodies, Anticardiolipin/immunology , Chi-Square Distribution , Enzyme-Linked Immunosorbent Assay , Female , Glycoproteins/immunology , Humans , Iodide Peroxidase/immunology , Logistic Models , Maternal Age , Middle Aged , Predictive Value of Tests , Pregnancy , Pregnancy Outcome , Prospective Studies , ROC Curve , Thyroglobulin/immunology , beta 2-Glycoprotein I
10.
Pediatr Med Chir ; 17(2): 107-10, 1995.
Article in Italian | MEDLINE | ID: mdl-7610070

ABSTRACT

A case of Munchausen syndrome by proxy in an infant presenting with recurrent vomiting and severe failure to thrive is described. Only very few cases of this syndrome have been reported in the italian literature in comparison to those described in the Anglo-Saxon countries. The factitious symptoms and signs fabricated or induced by parents lead to unnecessary medical investigation, hospital admissions and treatment. The Authors emphasize the difficulties in reaching a diagnosis and the risks of this potentially very dangerous behaviour in terms of morbidity and mortality. Since only one third of parents recover following psychotherapy, the offending parent should be sometimes separated from the child and promptly reported and closely supervised by the legal Authorities. Bizarre and otherwise peculiar, unexplained symptoms should always suggest the possibility of the Munchausen syndrome by proxy.


Subject(s)
Failure to Thrive/etiology , Gastrointestinal Diseases/etiology , Growth Disorders/etiology , Munchausen Syndrome by Proxy/complications , Vomiting/etiology , Child Abuse/legislation & jurisprudence , Failure to Thrive/psychology , Female , Gastrointestinal Diseases/psychology , Growth Disorders/psychology , Humans , Infant , Infant, Newborn , Italy , Jurisprudence , Munchausen Syndrome by Proxy/legislation & jurisprudence , Munchausen Syndrome by Proxy/psychology , Vomiting/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...